TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01107457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Ixekizumab
Description: Administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered subcutaneously
Study: NCT02850562

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Walking
Description: The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking + Exercise
Description: The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
Study: NCT03319888

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPAP
Description: continuous positive pressure in the airway

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conservative treatment
Description: conservative treatment group with lifestyle modifications
Study: NCT00520130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conditioning Chemotherapy
Description: Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.~Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMS
Description: Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLAG
Description: Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FLAG
Description: Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-F
Description: Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOCH-F
Description: Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alemtuzumab
Description: Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
Study: NCT04478435

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: glucose loaded clear fluid
Description: Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: glucose loaded clear fluid
Description: Ultrasound assessment of gastric antrum is done at different time interval following glucose loaded clear fluid ingestion
Study: NCT01083784

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of prophylactic anticonvulsants (valproate, clonazepam)
Description: start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Control group
Description: Control group
Study: NCT00007605

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sotalol
Description: Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
Study: NCT00960297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
Study: NCT00833157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: glucosamine sulphate
Description: Subjects are administered glucosamine-sulphate tablets of 500 mg \* 3 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ibuprofen
Description: Subjects are administered 600 mg \* 2 daily, while they are performing a strength-training program with both legs (\*3 weekly) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects are administered placebo tablets, while they are performing a strength-training program (\*3 weekly) with both legs for 12 weeks
Study: NCT03283410

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol plasmatic concentration (Marsh)
Study: NCT02210598

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: inpatient Foley balloon induction
Description: The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: outpatient Foley balloon induction
Description: The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxytocin
Description: When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L\&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.~Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement.
Study: NCT00690261

Intervention type: OTHER
Description: No intervention in this study
Study: NCT03960450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-475
Description: topical cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BOS-475
Description: topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical cream

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: topical cream
Study: NCT05657522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rapid molar intruder
Description: The rapid molar intruder was applied.
Study: NCT00864019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline HCl 100 mg tablets, single dose
Description: A: Experimental SSubjects received Purepac formulated products under non-fasting conditions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoloft® 100 mg tablets, single dose
Description: B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
Study: NCT03400085

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth application
Description: The intervention is an mHealth smartphone application designed for living kidney donors to complete their required 2-year follow-up. It allows the donor to input the answers to the clinical survey responses, as well as upload a picture of their lab values.
Study: NCT00187720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given a single oral dose of 850 mg of metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Subjects will be given a single oral dose of 850 mg of metformin
Study: NCT05093309

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Webinar
Description: At month 1 of the study period, the educational webinar was presented by expert speakers and consisted of 3 modules: 1) naloxone basics; 2) naloxone service implementation strategies; and 3) naloxone recommendation communication strategies. Participants were mailed naloxone nasal spray and auto-injector training devices prior to attending the online webinar so that they could follow along during demonstrations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resources
Description: After completing the baseline survey, both control and intervention groups were provided with a basic publicly available flyer about naloxone dosage forms in order to ensure all participants could provide adequate patient care.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reminders
Description: Reminders consisted of monthly emails from investigators for the purpose of retaining study engagement.
Study: NCT02856347

Intervention type: OTHER
Group type: OTHER
Intervention: 18F-DOPA
Description: Injection of 18F-DOPA and PET / CT-scan assessment
Study: NCT01141374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by needles
Description: The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: auriculotherapy by seeds
Description: We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
Study: NCT04253366

Intervention type: DEVICE
Group type: OTHER
Intervention: Clinical investigation device class IIa not marked CE
Description: Patients should perform MammoWave exam. A short visit should be performed and during this visit a qualitative differentiation would be performed between patients with high density breast, and patients with low density breast. After the patients will be ready for the MammoWave exam. The exam will be composed of two phases: the data acquisition and the data processing. During the acquisition that should takes about 10 minutes the patients would be lying in a prone position, on a bed which is part of the MammoWave. The upper part of MammoWave has a container cup shape, which contains the breast, which also has the function of separate it from the internal parts of the device. After patient is on the bed and MammoWave would start to perform the acquisition. Once the acquisition is completed, the data will be processed through an imaging algorithm, which is integrated in the device. The final output will be composed by one or more images, plus one or more parameters describing the images.
Study: NCT04255420

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPG Block
Description: A cotton-tipped applicator soaked in 1% lidocaine will be inserted into the nostril on the side of the headache. If the headache is bilateral, two cotton-tipped applicators will be inserted. The cotton-tipped applicators will be left in place for 15 minutes.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard IV Treatment
Description: Intravenous prochlorperazine 10 mg plus diphenhydramine 50 mg will be administered.
Study: NCT03100084

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling

Intervention type: OTHER
Intervention: Blood sampling
Description: Maternal blood sampling
Study: NCT04045925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taïso
Description: Taiso is a physical preparation practice of which the French Judo Federation is a state delegate. It is practiced in most French dojos. During each course, Taiso's practice works the fundamental motor skills (coordination, static and dynamic balance, locomotion and grip), muscle strengthening, target work by simulated attacks-defenses exercises without blows or projections, relaxation and the specific work of knowledge to fall and rise with graduation and progressivity in the intensity and complexity of the exercises as and when practiced.
Study: NCT02618577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:~Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein-P inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ASA
Description: ASA 100 mg tablets or Placebo, based on accepted indication for the latter, including peripherial or coronary artery disease, a prior myocardial infarction, or a prior stroke.
Study: NCT03597256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restylane Defyne
Description: Intradermal injection
Study: NCT04008186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone
Description: 50 mg capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam oral solution
Description: 2 mg/mL oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Repaglinide 1 MG
Description: 1 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MetFORMIN 500 Mg Oral Tablet
Description: 500 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: 10 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin tablet
Description: 0.25 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemfibrozil Tablets
Description: 600 mg tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole capsule
Description: 100 mg capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Verapamil Pill
Description: 120 mg tablet
Study: NCT04393012

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Provide alternative nurse call and communication device
Description: Evaluate impact of providing access to the nurse call system and a speech generating device.
Study: NCT01848808

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wobenzym PS

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00571090

Intervention type: PROCEDURE
Intervention: Thyroid ultrasonography
Description: Ultrasound-guided thyroid fine-needle aspiration biopsy
Study: NCT01817478

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: microbiologic sample
Study: NCT01989273

Intervention type: DEVICE
Intervention: Ultrasound of inferior vena cava

Intervention type: DEVICE
Intervention: Ultrasound of inferior vena cava
Study: NCT04737694

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ketone ester
Description: Oral ketone ester + glucose supplement

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Glucose supplement
Study: NCT02641353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Tablet
Description: 30 mg tablet
Study: NCT04319237

Intervention type: BEHAVIORAL
Intervention: Quality of Life (EQ-5D-5L) Questionnaire
Description: The EQ-5D-5L questionnaire is a self assessed quality of life questionnaire. The scale measures quality of life on a 5 component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The rater selects a number between 1-100 to describe the condition of their health, 100 being the best imaginable.

Intervention type: BEHAVIORAL
Intervention: PROMIS Cognitive Function 4a Questionnaire
Description: The PROMIS measures function, symptoms, behavior and feelings.
Study: NCT02641353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Oral Suspension
Description: 30 mg oral suspension

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apremilast Oral Suspension
Description: 30 mg oral suspension
Study: NCT01198548

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given IV

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT04721262

Intervention type: DEVICE
Intervention: Hyperfine Portable MRI
Description: The Hyperfine device is a newly developed MRI unit that has multiple potential advantages over standard CT or MRI including portability, easier upkeep, open design, and ease of use. Unlike CT, the Hyperfine device does not use moving parts or X-rays to generate images. Unlike routine MRI, the Hyperfine device uses two permanent magnets with open space between and around them, rather than a super-cooled superconducting magnetic tube. In contrast to CT and routine MRI, the device can be wheeled from place to place and moved into position with the patient remaining on a gurney or hospital bed. Relative to routine MRI, the device uses a very low magnetic field strength of 64 mT compared to 1.5 T or 3 T, making it safer for patients or environments with medical devices having metallic components.
Study: NCT02797730

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: art-therapy sessions
Study: NCT00504309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 4g P-OM3 capsules
Description: 4/day of 4g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4/day of 1g P-OM3 capsules
Description: 4/day of 1g P-OM3 capsules for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corn Oil Placebo, 4 capsules/day for 8 weeks
Description: 4 capsules per day of corn oil placebo for 8 weeks